[ Archive Home ]
Vicplas Intl| [ Archive Home ] |
| Vicplas Intl |
| Pages: 1 | 2 of 2 |
(Post 1 of 72) 12/14/1999.17:15:00 |
| Author : |
VICPLAS INTERNATIONAL LTD The Board of Directors of Vicplas International Ltd (hereinafter known as "the Company") is pleased to announce that the Company has recently acquired 2 subscribers' shares of RM1 each in each of the capital of Vicplas Industries (M) Sdn Bhd and Vicplas Marketing (M) Sdn Bhd from Messrs Chua Kim Hua and Loh Beng Seng who are subscribers for the purpose of registrating both the companies. Arising from the acquisition, Vicplas Industries (M) Sdn Bhd and Vicplas Marketing (M) Sdn Bhd became wholly owned subsidiaries of the Company. Vicplas Industries (M) Sdn Bhd and Vicplas Marketing (M) Sdn Bhd were both incorporated on 22 October 1999 with an authorised capital of RM100,000 each. Vicplas Industries (M) Sdn Bhd and Vicplas Marketing (M) Sdn Bhd have not commenced operations since its incorporation. The principal activities of Vicplas Industries (M) Sdn Bhd and Vicplas Marketing (M) Sdn Bhd are those of manufacturing, trading and distributing of uPVC pipes and pipe fittings. None of the substantial shareholders or the Directors of the Company have any interest in the acquisition other than through their respective shareholdings in the Companies. Submitted by Loh Beng Seng, Managing Director on 14 December 1999 to the SES |
| (Post 2 of 72) 02/24/2000.17:03:00 |
| Author : |
VICPLAS INTERNATIONAL LTD ANNOUNCEMENT Introduction The Board of Directors of Vicplas International Ltd (the "Company") is pleased to announce that Vicplas Holdings Pte Ltd ("VPHL"), a wholly-owned subsidiary of the Company had accepted an offer made by Jurong Town Corporation Limited's ("JTC") (the "JTC Offer"). Pursuant to the JTC Offer, VHPL will acquire a piece of land at Lot 2482T, Mukim No. 7, Private Lot A19621, Joo Koon Circle (the "Land") and erect on the Land a four-storey factory cum office building (the "Factory") (collectively the "Acquisition and Development). Rationale for the Acquisition and Development The Land has an area of approximately 9,000 square meters ('sqm'). The tenure of the land is for a period of 30 years commencing 1 February 2000 with an option to extend for a further term of 26 years subject to further investments specified by JTC. The proposed Factory will have a built-up area of approximately 15,600 sqm. The rationale of the Acquisition and Development is solely to accommodate the business operations of the Company and its subsidiaries (the "Group") and to meet the planned increased capacity requirement of the Group. Currently, the Group conducts its business operations at two different factories located in separate locations. The Group owns a factory premise at 18 Fan Yoong Road, Singapore 629795 that has a built-up area of 4,535 sqm. The lease for this leasehold property will expires on 23 November 2008. In addition, the Group rents an area of 9,897 square feet ("Sq ft") at 22 Jurong Port Road, Singapore 619114. The rental lease is subject to an annual review. In view of the short remaining lease tenure of its existing property and the yearly review of the rental lease, the Acquisition and Development will allow the Group an opportune time to consolidate its existing operations at a single location. These will improve the operational work flow of the Group's manufacturing process. The Group expects to reduce travelling time, transportation costs and increase efficiency in the flow of the production process. To meet the Group's planned business expansion and increasing capacity requirements, additional production floor space will be required. The Group expects to fully utilise the entire four floors of the Factory upon completion of the construction. In view of the foregoing, the Directors are of the view that the Acquisition and Development is in the interest of shareholders. Purchase Consideration The aggregate consideration for the Acquisition and Development is approximately S$11 million (the "Consideration"). The Consideration constitutes approximately 96% of the Group's net tangible assets as at the last financial year ended 31 July 1999. The Acquisition and Development will be financed from internal and external sources. Approximately S$3 million of the Consideration will be funded from proceeds of the Company's initial public offering as disclosed on page 18 of the Company's Prospectus dated 13 April 1999. In the interim, the remaining amount of S$8 million will be financed from external sources. The Directors will, at an appropriate time, consider the divestiture of its existing property. The Directors will also, from time to time, consider other funding alternatives, after taking into account the Group's future growth plans. Financial Effects The Acquisition and Development will not change the Company's issued share capital. The Acquisition and Development is also not expected to have any material impact on the Group's financial results for the financial year ending 31 July 2000 as the Acquisition and Development is expected to commence only around April 2000. The Acquisition and Development is also not expected to have any material effect on the Group's net tangible asset backing as at 31 July 2000. Interest of Directors and Major Shareholders None of the Directors or substantial shareholders of the Company has any direct or indirect interest in the proposed Acquisition and Development. Submitted by Loh Beng Seng, Managing Director on 24/02/2000 to the SES |
| (Post 3 of 72) 03/29/2000.07:30:00 |
| Author : |
VICPLAS INTERNATIONAL LTD ACQUISITION OF 51% OF FUTURE PRESS PTE LTD The Board of Directors of Vicplas International Ltd (hereinafter known as "the Company") is pleased to announce that the Company has entered into an Agreement with DIS Solution Pte Ltd (hereinafter known as "DIS") and Inkjet Direct Pte Ltd (hereinafter known as "Inkjet") to subscribe for 520,000 shares of S$1/- each in the capital of Future Press Pte Ltd (hereinafter known as "FPPL") representing 51% of the issued share capital for a total consideration of S$561,600/-. The remaining 49% of the issued share capital of FPPL are held by DIS (9.8%) and Inkjet (39.2%). Arising from this acquisition, FPPL became a subsidiary of the Company. FPPL was incorporated in Singapore on 14 April 1998. The principal activities of FPPL are to provide a range of cost effective, large format, short run, quality digital printing and a range of further services to a multitude of clients. For the six months ended 30 Nov 1999, FPPL recorded a profit before tax of S$25,260. This acquisition, which will be financed through internal resources, is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Company for the financial year ending 31 July 2000. Save as disclosed above, none of the substantial shareholders or the Directors of the Company have any direct or indirect interest in the acquisition other than through their respective shareholdings in the Company. Submitted by Loh Beng Seng, Managing Director on 28/03/2000 to the SES |
| (Post 4 of 72) 04/27/2000.06:33:00 |
| Author : |
Vicplas 1H Net S$509,00 Vs S$1.4M Vicplas International Ltd. 1H To Jan. 31: 2000 Net Profit S$509,000 vs S$1,405,000 Pretax Profit 683,000 vs 1,405,000 Revenue 7,156,000 vs 7,301,000 Per Share Net Profit 0.39 cent vs 1.41 cents Dividend Omitted vs Omitted |
| (Post 5 of 72) 05/25/2000.02:10:00 |
| Author : |
INCORPORATION OF A WHOLLY OWNED SUBSIDIARY The Board of Directors of Vicplas International Ltd ("the Company" or "Vicplas") wishes to announce that the Company has incorprated a wholly owned subsidiary known as Forefront Medical Technology (Pte) Ltd ("Forefront Medical"). Frontfront Medical was incorporated in Singapore with an authorised share capital of S$1,000,000 divided into 1,000,000 ordinary shares of S$1.00 each and a issued and paid-up share capital of S$2 divided into 2 ordinary shares of S$1.00 each. The 2 subscriber shares were held initially on trust for the Company by Mr. Loh Beng Seng and Mr. Cheng Liang, the Managing Director and Executive Director of Vicplas respectively, and upon incorporation, were transferred to Vicplas at par. The intended objective of Forefront Medical is to manufacture medical instruments. Forefront Medical has yet to commence operations. Submitted by Christine Tan, Company Secretary on 24/5/2000 to the SES |
| (Post 6 of 72) 07/02/2000.02:22:00 |
| Author : |
MY FEELING...UP TO .49, THEN DOWN! |
| (Post 7 of 72) 07/04/2000.10:23:00 |
| Author : |
VICPLAS INTERNATIONAL LTD REQUEST FOR SUSPENSION OF TRADING OF SHARES ON THE SINGAPORE EXCHANGE LIMITED The Company wishes to request for a suspension of trading of its shares with effect from 9:00 a.m. on 4 July 2000, pending an announcement to be made by the Company. Submitted by Christine Tan, Company Secretary on 03/07/2000 to the SGX |
| (Post 8 of 72) 07/04/2000.22:12:00 |
| Author : |
Vicplas, LMA International in jv to manufacture clinical airway devices SINGAPORE (AFX-ASIA) - Vicplas International Ltd said it has set up a 50: 50 joint venture company with Panama-based LMA International SA to manufacture components for LMA International's air management devices for medical facilities. The jv company will be called Forefront Medical Technology Pte Ltd "This marks our entry into a new business arena, and one that has significant growth potential for Vicplas," said Victor Loh, managing director of Vicplas International. str/jb/tr |
| (Post 9 of 72) 07/04/2000.23:18:00 |
| Author : |
NEWS RELEASE VICPLAS DIVERSIFIES INTO MEDICAL SECTOR - TO MANUFACTURE AIRWAY MANAGEMENT DEVICES THROUGH JV WITH LMA INTERNATIONAL SA Sesdaq-listed VicPlas International Ltd ("VicPlas") announced today (July 4, 2000) that it has entered into a joint venture with LMA International SA ("LMA International") to manufacture components for its range of LMATM airway management devices. Under the joint venture, VicPlas and LMA International have respectively subscribed for 249,998 and 250,000 ordinary shares of S$1.00 each for cash at par in the capital of the joint venture vehicle, Forefront Medical Technology Pte Ltd ("Forefront Medical"), which was incorporated on April 1, 2000. VicPlas and LMA International will each hold 50% of the share capital of Forefront Medical. Under the joint venture agreement, LMA International will license technological know-how to Forefront Medical and will provide the moulds and equipment for the manufacture of the products components. Forefront Medical will manufacture LMATM components for a variety of products in the LMATM range for subsequent assembly by LMA International's existing manufacturers. The assembled products will be sold through LMA International's network of subsidiary and independent distribution companies in 80 countries. Commenting on the joint venture, Mr Victor Loh, Managing Director of VicPlas, said: "This marks our entry into a new business arena, and one that has significant growth potential for VicPlas. This move is in line with our strategy of identifying opportunities to move into fast-track, rapid-growth businesses and industries as a means to widen our earnings base, diversify our business, and still utilise our core competencies in plastics manufacturing. The LMATM is a leading edge product and its widespread endorsement by clinicians worldwide, together with the global presence of LMA International, provides us with an established product and market from which to grow our business." Mr Robert Gaines Cooper, Group Chairman of LMA International, added: "This is an exciting new partnership for us. VicPlas is a natural partner for us, having been in the business of plastics manufacture for close to a decade, with an excellent reputation in the industry, and with a strong local market knowledge. Singapore provides us with an excellent location for our new venture. It is a country which actively encourages and supports commercial activities and which recognises and protects intellectual property. This is exactly the type of environment in which product development can thrive. To a company such as LMA International, committed as it is to the development of proprietary, innovative products, this is very important." Forefront Medical is expected to commence operations in September this year. Mr Victor Loh and Mr Cheng Liang, an Executive Director of VicPlas, have been appointed Managing Director and Director of Forefront Medical respectively. The joint venture is not expected to have any material effect on the earnings per share and net tangible assets per share of VicPlas for the financial year ending July 31, 2000. VicPlas International Ltd VicPlas was established in 1993 and listed in 1999. The Group is a leading niche manufacturer and distributor of quality uPVC pipes and pipe fittings, serving more than 200 customers in sanitary and plumbing, cable laying and electrical industries. VicPlas manufactures an extensive range of over 400 types of uPVC pipes and pipe fittings. The Group has in-house expertise to manufacture products ranging from very small plastic parts weighing 5 g to large plastic parts weighing 3.5 kg each. The products can broadly be categorized into the following main groups: - sanitary and plumbing: uPVC pipes and pipe fittings, including accessories; - cable-laying: uPVC pipes and cable cover plates; and - electrical: electrical conduits and accessories, corrugated conduits and accessories. LMA International SA LMA International SA is a privately owned company, incorporated in the Republic of Panama. LMA International is the parent company of The Laryngeal Mask Company Limited which holds the commercialisation rights worldwide (except the UK and Eire) for the LMATM range of products. The LMATM is an innovative airway management device, which since its introduction in 1989, has successfully challenged the traditional concept and practice of airway management. Over one million devices have been sold worldwide. LMATM products have been endorsed by anaesthetists worldwide and are supported by over 2,000 publications in medical journals. The Company is committed to an ongoing programme of new product development and research that aims to continue to extend the boundaries of traditional anaesthesia. LMATM is a registered trademark of The Laryngeal Mask Company Limited and all references in the press release are to this trademark. July 4, 2000 Submitted by Christine Tan, Company Secretary on 04/07/2000 to the SGX |
| (Post 10 of 72) 07/07/2000.16:48:00 |
| Author : |
Just noticed that an individual by the name of Michael Chan sold a major block of shares at $0.439 on 3 July reducing his stake from 6.33% to 4.04%. What great timing! Shares have fallen 18% since then. Any idea who this person is? Here is a listing of the directors, MC is not on the board. Chua Kim Hua Chairman Loh Beng Seng MD Cheng Liang ED Lim Hock Beng Ang Mong Seng |
| (Post 11 of 72) 08/09/2000.10:34:00 |
| Author : |
Another counter long forgone by alot of investor.. See this counter fly in the next few days |
| (Post 12 of 72) 09/23/2000.12:23:24 |
| Author : |
PROPOSED PRIVATE PLACEMENT OF 13, 000, 000 NEW ORDINARY SHARES OF S$0.05 EACH IN THE CAPITAL OF VICPLAS INTERNATIONAL LTD AT S$0.23 PER ORDINARY SHARE (THE "PRIVATE PLACEMENT")
The Directors of Vicplas International Ltd (the "Company") are pleased to announce that the Company has signed a subscription agreement on 23 September 2000 with Lum Chang Securities Pte Ltd ("Lum Chang") pursuant to which Lum Chang has agreed to subscribe or procure subscription for 13,000,000 new ordinary shares of par value S$0.05 each in the capital of the Company (the "New Shares") at S$0.23 per New Share for an aggregate consideration of S$2.99 million. The Placement Price of S$0.23 for each New Share represents a discount of approximately 5.62% of the weighted average price of the Company's shares for trades done on Singapore Exchange Dealing and Automated Quotation System ("SGX - Sesdaq") on 22 September 2000. The New Shares, when issued and fully paid, will rank pari passu in all respects with the ordinary shares of the Company existing at the time of issue of the New Shares. The Private Placement is conditional upon, inter alia, in-principle approval being granted by the Singapore Exchange Securities Trading Limited ("SGX-ST") for the listing of and quotation for the New Shares on the SGX - Sesdaq. The estimated net proceeds of the Private Placement of approximately S$2.94 million will be used as follows: 2. approximately $0.94 million for business expansion and to further strengthen the working capital of the Company and its subsidiaries (the "Group"). Pending the deployment of the net proceeds, such proceeds may be placed as deposits with financial institutions or invested in short term money market instruments or to reduce bank borrowings, as the Directors may deem fit. When completed, the Private Placement will increase the issued share capital of the Company from S$6,550,000 divided into 131,000,000 shares of S$0.05 to S$7,200,000 divided into 144,000,000 shares of S$0.05 each. The New Shares represent approximately 9.9% of the issued share capital of the Company as at 18 September 2000. Based on the audited accounts of the Company and its subsidiaries (the "Group") as at 31 July 1999, the net tangible assets per share of the Company and the Group, after adjusting for the New Shares will change from approximately S$0.0747 to S$0.0884 and S$0.0874 to S$0.0999 respectively. The approval of the shareholders to authorise the Directors of the Company pursuant to Section 161 of the Singapore Companies Act (Cap 50) to issue new shares not exceeding 20% of the Company's issued share capital for the time being was obtained at the annual general meeting of the Company held on 18 January 2000. None of the New Shares will be placed with the Directors or substantial shareholders of the Company or any of their respective related parties. None of the Directors or substantial shareholders of the Company has any interest, direct or indirectly, in the Private Placement By Order of the Board Vicplas International Ltd Submitted by Loh Beng Seng, Managing Director on 23/09/2000 to the SGX |
| (Post 13 of 72) 09/26/2000.00:36:42 |
| Author : |
Vicplas International to place 13 mln new shares at 0.23 sgd/shr
SINGAPORE (AFX-ASIA) - Vicplas International Ltd said it has signed a subscription agreement with Lum Chang Securities Pte Ltd to place 13.0 mln new shares at 0.23 sgd per share. Under the agreement, Lum Chang will subscribe to shares amounting to 2.99 mln sgd. The placement price of 0.23 sgd per new share represents a discount of about 5.62 pct of the weighted average price of the shares, the company said in a statement. Net proceeds are estimated at 2.94 mln sgd. Of the total proceeds, about 2.0 mln sgd will be used to partially finance the construction costs of the development of a four-storey factory cum office building in Joo Koon Circle, it added. About 0.94 mln sgd will be used for business expansion and to further strengthen the company's working capital. Pending the deployment of the net proceeds, it may be placed as deposits with financial institutions or invested in short-term money market instruments or to reduce bank borrowings. The private placement will increase the issued share capital Vicplas by about 9.9 pct, the company added. |
| (Post 14 of 72) 10/06/2000.03:55:56 |
| Author : |
PROPOSED PRIVATE PLACEMENT OF 13, 000, 000 NEW ORDINARY SHARES OF S$0.05 EACH IN THE CAPITAL OF VICPLAS INTERNATIONAL LTD AT S$0.23 PER ORDINARY SHARE (THE "PRIVATE PLACEMENT")
The Directors of Vicplas International Ltd (the "Company") are pleased to announce that the Singapore Exchange Securities Trading Ltd ("SGX-ST") has today approved in-principle the Company's application for the listing and quotation of 13,000,000 new ordinary shares of S$0.05 each (the "Placement Shares") in the issued and paid-up capital of the Company on the Official List of the Singapore Exchange Dealing and Automated Quotation System ("SGX-Sesdaq"). Such approval-in-principle by SGX-ST is not to be taken as an indication of the merits of the Private Placement or the Placement Shares. As announced on 23 September 2000, the Company had on that date entered into a Subscription Agreement with Lum Chang Securities Pte Ltd ("Lum Chang Securities"), whereby Lum Chang Securities had agreed to subscribe or to procure subscriptions for the Placement Shares at a placement price of S$0.23 per Placement Share. By Order of the Board Vicplas International Ltd Submitted by Loh Beng Seng, Managing Director on 05/09/2000 to the SGX |
| (Post 15 of 72) 11/01/2000.01:19:26 |
| Author : |
Vicplas Intl FY Net S$119,000 Vs S$2.5M
Source : Dow Jones 17:44 31/10/2000 Full Year to July 31: - 2000 vs 1999 Net Profit - S$119,000 vs S$2,528,000 Pretax Profit - 220,000 vs 3,590,000 Revenue - 15,814,000 vs 17,358,000 Per Share Net Profit - 0.09 cents vs 2.35 cents Dividend - omitted - omitted Earnings per share is based on issued share capital. |
| (Post 16 of 72) 01/13/2001.00:21:39 |
| Author : |
ANNOUNCEMENT
In response to the letter from the Singapore Exchange Limited dated 8 January 2001, the Directors of the Company would like to disclose the following additional information in relation to the Annual Report for the year ended 31 July 2000. (a) That the transactions conducted pursuant to the shareholders' mandate obtained for Interested Person Transactions are as follows:
(b) There were no non-audit fees paid to the auditors during the financial year ended 31 July 2000. Submitted by Christine Tan, Company Secretary on 12/01/2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
